Date: 2014-04-24
Type of information: Collaboration agreement
Compound: MultiStem®
Company: Cell Therapy Catapult (UK) Athersys (USA - OH)
Therapeutic area: Regenerative medicine
Type agreement: collaboration
Action mechanism: stem cell therapy.MultiStem® cell therapy is a patented regenerative medicine product that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage. MultiStem has demonstrated therapeutic potential for the treatment of inflammatory and immune disorders, neurological conditions, and cardiovascular disease, as well as other areas. It represents a unique \"off-the-shelf\" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression.
Disease:
Details: * On April 24, 2014, The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation\'s health and wealth, has announced that it is working with Athersys on multiple projects to progress the development of Athersys’ MultiStem® cell therapy product in Europe. Among the projects, Cell Therapy Catapult will undertake a European market access assessment for the MultiStem product which considers factors such as data requirements for evidence-based decision making, payers\' value perceptions and pricing benchmarks. Athersys’ proprietary MultiStem cell therapy is an ‘off the shelf’ stem cell product in development for the treatment of multiple distinct diseases and conditions in the cardiovascular, neurological, inflammatory and immune disease areas. The product, which consists of multipotent adult progenitor cells obtained from healthy, consenting donors, is produced from human stem cells obtained from adult bone marrow or other tissue sources. Unlike traditional bone marrow transplants, the resulting product may be manufactured on a large scale, ensuring product consistency, and exhibits a \'drug -like\' profile. Currently, MultiStem is the subject of five clinical programmes, and is also being assessed in preclinical studies in a range of indications.
Financial terms:
Latest news:
